Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 14:8:100213.
doi: 10.1016/j.jhlto.2025.100213. eCollection 2025 May.

Sotatercept Use in a Patient with Pulmonary Arterial Hypertension Undergoing Lung Transplantation

Justin P Rosenheck  1 , Kashika Goyal  1 , Tara Fallah  2 , Pamela Burcham  2 , Kukbin Choi  3 , Matthew Henn  3 , Elie Homsy  1 , Scott Visovatti  4 , Veronica Franco  4
Affiliations

Sotatercept Use in a Patient with Pulmonary Arterial Hypertension Undergoing Lung Transplantation

Justin P Rosenheck et al. JHLT Open. .

Abstract

Pulmonary arterial hypertension (PAH) is one of the common indications for lung transplantation. Sotatercept is a new medication with a novel mechanism of action and was recently approved for the treatment of PAH. Sotatercept is associated with significant adverse effects including thrombocytopenia and erythrocytosis which can impact outcomes of lung transplantation. This is the first described case of a patient undergoing lung transplantation while receiving sotatercept for PAH.

Keywords: Group 1; Lung Transplant; PAH; Pulmonary Arterial Hypertension; Sotatercept.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Veronica Franco reports a relationship with Merck & Co Inc that includes: consulting or advisory. Veronica Franco reports a relationship with Gossamer Bio Inc that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Timeline of Therapies and Hemodynamic Assessments. Abbreviations: Maci: Macitentan; Rio: Riociguat; Sil: Sildanefil; Sot: Sotatercept; Tad: Tadalafil; Trep: treprostinil; IV: Intravenous; qd: every day; PO: Per Oral; SQ: Subcutaneous; TID: three times daily.
Figure 2
Figure 2
Lab Values on Sotatercept Peri-Transplant.
See this image and copyright information in PMC

References

    1. Chin K.M., Gaine S.P., Gerges C., et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64 doi: 10.1183/13993003.01325-2024. - DOI - PMC - PubMed
    1. Condon D.F., Agarwal S., Chakraborty A., et al. Novel mechanisms targeted by drug trials in pulmonary arterial hypertension. Chest. 2022;161:1060–1072. doi: 10.1016/j.chest.2021.10.010. - DOI - PMC - PubMed
    1. Hoeper M.M., Badesch D.B., Ghofrani H.A., et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388:1478–1490. doi: 10.1056/NEJMoa2213558. - DOI - PubMed
    1. McLaughlin V., Alsumali A., Liu R., et al. Population health model predicting the long-term impact of sotatercept on morbidity and mortality in patients with pulmonary arterial hypertension (PAH) Adv Ther. 2024;41:130–151. doi: 10.1007/s12325-023-02684-x. - DOI - PMC - PubMed
    1. Ait-Oudhia S., Jaworowicz D., Hu Z., et al. Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension. CPT Pharmacometrics Syst Pharmacol. 2024;13:1380–1393. doi: 10.1002/psp4.13166. - DOI - PMC - PubMed

LinkOut - more resources